ClinicalTrials.gg
CompletedNCT01582477TAPUpdated Jun 14, 2021Results posted

TAP-patients With Robotic Assisted Lap Prostatectomy

A Phase 4 interventional study of EXPAREL 20 mL and EXPAREL 40 mL in Postsurgical Pain, Analgesia and Prostatectomy, sponsored by Pacira Pharmaceuticals, Inc. Completed at 1 site in United States. Open to male participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-06-14.

Sponsored by Pacira Pharmaceuticals, Inc · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
24
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 93 studies testing Liposomal Bupivacaine in Pain, Postoperative — 14 open to participants now, 15 under way, 2 of them phase 3. Liposomal Bupivacaine · Pain, Postoperative.

Enrollment
75th of 93
24 · median 80
Started
2012
with 5 others
Phase 4
52 of 93
5 open now
Registered
1st of 93
by date
Lead sponsor
11 of 93
Pacira Pharmaceuticals, Inc

Among the 93 studies testing Liposomal Bupivacaine in Pain, Postoperative, this one is the 75th largest by enrollment, is one of 6 that started in 2012, is one of 52 in phase 4, and was the 1st registered.

Pain, Postoperative

5,654 studies on the registry are indexed under Pain, Postoperative; 1,233 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

14 of the 93 studies testing Liposomal Bupivacaine in Pain, Postoperative are open now, in 3 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 14 open studies →

About Liposomal Bupivacaine

Liposomal Bupivacaine: first FDA approval 2011 (EXPAREL), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 676 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 327 (48%) stop at 75 or younger; 74 take children under 18; 128 take healthy volunteers.

This study: 18 Years to 75 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 93 studies testing Liposomal Bupivacaine in Pain, Postoperative, or all of them as a file.
02

Study summary

The purpose of the study is to assess the safety and efficacy of EXPAREL when administered via infiltration into the transversus abdominis plane (TAP) to prolonged postsurgical analgesia in men undergoing robot-assisted laparoscopic prostatectomy.

Read the detailed description

Assess the safety and efficacy of EXPAREL when administered via infiltration into the transversus abdominis plane (TAP) to provide prolonged postsurgical analgesia in men undergoing robot-assisted laparoscopic prostatectomy. The primary endpoint is the duration of abdominal analgesia from the infiltration into the TAP as measured by the time to the subject's first postsurgical opioid administration.

03

Conditions studied

  • Postsurgical Pain
  • Analgesia
  • Prostatectomy

Browse trials for

Keywords

  • TAP, robot-assisted prostatectomy
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • male subjects, aged 18-75.
  • American Society of Anesthesiology (ASA) physical status 1-3.
  • Undergoing robot-assisted laparoscopic prostatectomy performed by a single surgeon (Ingolf Tuerk, MD).
  • Subjects must be physically and mentally able to participate in the study and complete all study assessments.
  • Subjects must be able to give fully to participate in this study after demonstrating a good understanding of the risks and benefits of the TAP infiltration.

Exclusion criteria

Exclusion Criteria:

  • Demonstrated or idiosyncratic reactions to amide-type local anesthetics.
  • Inability to tolerate oxycodone with acetaminophen (e.g. Percocet).
  • Any subject whose anatomy or surgical procedure in the opinion of the Investigator might preclude the potential successful performance of a TAP.
  • Any subject who in the opinion of the Investigator might be harmed or be a poor candidate for participation in the study.
  • Subjects who have received any drug within 30 days prior to study drug administration or planned administration of another investigational product or procedure during their participation in this study.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    EXPAREL 20 mL (undiluted)

    20 mL (266 mg) undiluted EXPAREL with 133 mg infiltrated on each the right and left side of the abdomen.

    Drug: EXPAREL 20 mL

  • Active comparator
    EXPAREL 40 mL (diluted)

    20 mL (266 mg) EXPAREL diluted with an equal volume of preservative-free 0.9% normal saline to a total of 40 mL and infiltrated equally to the right and left side of the abdomen.

    Drug: EXPAREL 40 mL

Interventions

  • EXPAREL 266 mg (undiluted)

    Also known as: bupivacaine liposome injectable suspension

  • EXPAREL 266 mg diluted with preservative-free 0.9% normal saline to 40 mL.

    Also known as: bupivacaine liposome injectable suspension

06

What researchers measure

Primary outcomes

  1. The Duration of Abdominal Analgesia From Infiltration Into the TAP

    Time frame: First postsurgical administration of an opioid

Secondary outcomes

  1. Subject Reported Postsurgical Pain

    11-point numeric rating scale (NRS) (0-10, where 0=no pain, 10=worst possible pain)

    Time frame: 1, 2, 6, 12, 24, 48, 72, 96 hours and 10 days after TAP

  2. Physician/Healthcare Professional Assessed Postsurgical Pain

    11-point NRS (0-10, 0=no pain, 10=worst possible pain)

    Time frame: 1, 2, 6, 12, 24 hours after TAP

  3. Total Postsurgical Oxycodone/Acetaminophen Consumption From Hospital Discharge Through Hour 96.

    Number of pills

    Time frame: 48, 72, 96 hours

  4. Incidence of Prespecified Opioid-related Adverse Events

    Number of subjects

    Time frame: Until hospital discharge order was written, anticipated at 24 hours.

  5. Overall Rating of Subject Satisfaction With Postsurgical Pain Control

    Mean of subject satisfaction offered on a 5-point Likert scale (1 = extremely dissatisfied, 2 = dissatisfied, 3 = neither satisfied nor dissatisfied, 4 = satisfied, 5 = extremely satisfied)

    Time frame: 24 hours, 72 hours, and day 10

07

Results

Posted Jun 10, 2013

Participant flow

Participant flow — Overall Study
MilestoneEXPAREL 20 mLEXPAREL 40 mL
Started1212
Completed1212
Not completed00

Outcome measures

PrimaryThe Duration of Abdominal Analgesia From Infiltration Into the TAP
Time frame:
First postsurgical administration of an opioid
Reported as:
Median · hours
The Duration of Abdominal Analgesia From Infiltration Into the TAP
hoursEXPAREL 20 mLEXPAREL 40 mL
The Duration of Abdominal Analgesia From Infiltration Into the TAP0.39 (0.27 to 0.60)0.44 (0.40 to 0.58)
SecondarySubject Reported Postsurgical Pain

11-point numeric rating scale (NRS) (0-10, where 0=no pain, 10=worst possible pain)

Time frame:
1, 2, 6, 12, 24, 48, 72, 96 hours and 10 days after TAP
Reported as:
Mean · units on a scale
Subject Reported Postsurgical Pain
units on a scaleEXPAREL 20 mLEXPAREL 40 mL
1 hour after TAP4.4 ± 2.575.3 ± 2.35
2 hours after TAP3.1 ± 1.53.9 ± 2.15
6 hours after TAP2.4 ± 1.573.0 ± 2.10
12 hours after TAP2.5 ± 2.122.2 ± 1.60
24 hours after TAP1.8 ± 1.752.5 ± 1.68
48 hours after TAP2.0 ± 1.542.5 ± 2.61
72 hours after TAP1.8 ± 1.641.9 ± 1.83
96 hours after TAP1.1 ± 1.081.7 ± 2.06
Day 10 after TAP0.00 ± 0.001.0 ± 1.55
SecondaryPhysician/Healthcare Professional Assessed Postsurgical Pain

11-point NRS (0-10, 0=no pain, 10=worst possible pain)

Time frame:
1, 2, 6, 12, 24 hours after TAP
Reported as:
Mean · units on a scale
Physician/Healthcare Professional Assessed Postsurgical Pain
units on a scaleEXPAREL 20 mLEXPAREL 40 mL
1 hour after TAP4.2 ± 2.335.3 ± 2.35
2 hours after TAP2.9 ± 1.563.9 ± 2.15
6 hours after TAP2.4 ± 1.573.0 ± 2.10
12 hours after TAP2.6 ± 2.072.2 ± 1.33
24 hours after TAP1.8 ± 1.752.5 ± 1.68
SecondaryTotal Postsurgical Oxycodone/Acetaminophen Consumption From Hospital Discharge Through Hour 96.

Number of pills

Time frame:
48, 72, 96 hours
Reported as:
Mean · Number of tablets
Total Postsurgical Oxycodone/Acetaminophen Consumption From Hospital Discharge Through Hour 96.
Number of tabletsEXPAREL 20 mLEXPAREL 40 mL
48 hours1.9 ± 2.112.2 ± 2.12
72 hours2.8 ± 3.213.4 ± 3.75
96 hours3.7 ± 4.254.8 ± 5.33
SecondaryIncidence of Prespecified Opioid-related Adverse Events

Number of subjects

Time frame:
Until hospital discharge order was written, anticipated at 24 hours.
Reported as:
Number · Number of subjects
Incidence of Prespecified Opioid-related Adverse Events
Number of subjectsEXPAREL 20 mLEXPAREL 40 mL
Incidence of Prespecified Opioid-related Adverse Events00
SecondaryOverall Rating of Subject Satisfaction With Postsurgical Pain Control

Mean of subject satisfaction offered on a 5-point Likert scale (1 = extremely dissatisfied, 2 = dissatisfied, 3 = neither satisfied nor dissatisfied, 4 = satisfied, 5 = extremely satisfied)

Time frame:
24 hours, 72 hours, and day 10
Reported as:
Count of participants · Participants
Overall Rating of Subject Satisfaction With Postsurgical Pain Control
ParticipantsEXPAREL 20 mLEXPAREL 40 mL
24 hours- satisfied45
24 hours- extremely satisfied87
72 hours - satisfied44
72 hours - extremely satisfied77
Day 10 - satisfied34
Day 10- extremely satisfied87

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
EXPAREL 20 mL—3/12 (25%)0/12 (0%)
EXPAREL 40 mL—0/12 (0%)1/12 (8.3%)
Most frequent serious events
Most frequent serious events
EventEXPAREL 20 mLEXPAREL 40 mL
Post-procedural HematomaVascular disorders1/120/12
Pulmonary EmbolismVascular disorders1/120/12
PyrexiaGeneral disorders1/120/12
Most frequent other events
Most frequent other events
EventEXPAREL 20 mLEXPAREL 40 mL
Joint StiffnessMusculoskeletal and connective tissue disorders0/121/12
Joint SwellingMusculoskeletal and connective tissue disorders0/121/12

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)EXPAREL 20 mLEXPAREL 40 mLTotal
<=18 years000
Between 18 and 65 years6915
>=65 years639
Age, Continuous
Age, Continuous(years)EXPAREL 20 mLEXPAREL 40 mLTotal
Mean60.7 ± 7.2461.7 ± 7.0161.2 ± 6.99
Sex: Female, Male
Sex: Female, Male(Participants)EXPAREL 20 mLEXPAREL 40 mLTotal
Female000
Male121224
Region of Enrollment
Region of Enrollment(participants)EXPAREL 20 mLEXPAREL 40 mLTotal
United States121224
08

Study locations

1 site
  • Steward St. Elizabeth's
    Brighton, Massachusetts 02135, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2012, a primary completion of May 2012 and a completion of Jul 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2013, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 19, 2012
First posted
Apr 20, 2012
Start
Mar 2012
Primary completionActual
May 2012
CompletionActual
Jul 2012
Results first posted
Jun 10, 2013
Last update
Jun 14, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 14, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01582477
Responsible party
Sponsor
First posted
Apr 20, 2012
Start date
Mar 2012
Primary completion
May 2012
Completion
Jul 2012
Results posted
Jun 10, 2013
Last update
Jun 14, 2021

Study contacts

Andrew Sternlicht, MD
principal investigator · Steward St. Elizabeth's

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Liposomal Bupivacaine

Start the discussion